Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - buprenorphine, quantity: 10 mg - drug delivery system, transdermal - excipient ingredients: oleyl oleate; povidone; levulinic acid; polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; heptane; aluminium acetylacetonate - bupredermal patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. bupredermal patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. bupredermal patches are not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - buprenorphine, quantity: 5 mg - drug delivery system, transdermal - excipient ingredients: levulinic acid; oleyl oleate; povidone; polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; heptane; aluminium acetylacetonate - bupredermal patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. bupredermal patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. bupredermal patches are not indicated as an as-needed (prn) analgesia.

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - fentanyl (unii: uf599785jz) (fentanyl - unii:uf599785jz) - fentanyl 12 ug in 1 h - fentanyl transdermal system is a transdermal formulation of fentanyl indicated for the management of persistent, moderate to severe chronic pain in opioid-tolerant patients 2 years of age and older when a continuous, around-the-clock opioid analgesic is required for an extended period of time, and the patient cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate-release opioids. patients considered opioid-tolerant are those who are taking at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily, or an equianalgesic dose of another opioid for a week or longer. fentanyl transdermal system is contraindicated in the following patients and situations due to the risk of fatal respiratory depression: fentanyl transdermal system is also contraindicated: pregnancy c: there are no adequate and well-controlled studies in pregnant women. fentanyl transdermal system should be used during pregnancy only

Canada - English - Health Canada

sanofi-aventis canada inc - tretinoin - cream - 0.05% - tretinoin 0.05% - cell stimulants and proliferants

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

dowelhurst ltd - clobetasone butyrate - cutaneous cream - 500microgram/1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - clobetasone butyrate - cutaneous cream - 500microgram/1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - clobetasone butyrate - cutaneous cream - 500microgram/1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - clobetasone butyrate - cutaneous cream - 500microgram/1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - clobetasone butyrate - cutaneous cream - 500microgram/1gram

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - clobetasol propionate 0.525 mg/g;   - topical cream - 0.05% w/w - active: clobetasol propionate 0.525 mg/g   excipient: cetostearyl alcohol chlorocresol citric acid monohydrate glyceryl monostearate polyoxyethylene-glycerin monostearate propylene glycol purified water sodium citrate dihydrate white beeswax - treatment of resistant dermatoses such as psoriasis (excluding widespread plaque psoriasis), recalcitrant eczemas, lichen planus and discoid lupus erythematosus and other skin conditions which do not respond satisfactorily to less active steroids.